血管紧张素

Plasma concentration of both Ang Ⅱ and ALDO returned to predepletion levels after third sodium depletion 5 days,but ANP was inhibited.

大鼠经3次钠缺乏恢复正常生活5d时，对血管紧张素Ⅱ、醛固酮的分泌量没有影响，而使心房肽的分泌受到抑制。

The morning venous blood was collected to determine the serum level of glyceryl trinitrate, cholesterol and the plasma level of Ox-LDL, malondyladehyde and superoxide dismutase before administration and 8, 16 weeks after.

本研究旨在探讨高血压病患者是否存在血浆Ox-LDL增高现象，口服化学结构无巯基的血管紧张素转换酶抑制剂降压的同时，是否会对Ox-LDL产生影响。

The expression of AT1 and AT2 receptor was examined in ureteric bud cell of the embryonic mouse, including embryonic days 12, 14, 15, 16 by immunohistochemical technique.

采用免疫组织化学方法检测胚龄12，14，15，16 d小鼠肾脏发育早期输尿管芽分支中血管紧张素Ⅱ受体1和受体2的含量。

We inestigated functional coupling of the receptors by measuring contractility in isolated trabeculae stimulated with increasing concentrations of angiotensin II.

我们增加血管紧张素II的浓度来刺激离体心肌小节，通过测量心肌小节的收缩性来探索受体的功能偶联。

Strong heart mao is still treatment CHF of tradition position, from 80's blood vessel strain ACEI drive clinical extensive application, get by its special pharmacology foundation quick development, particularly three new ACEI, make CHF treatment put off to a later time solution symptom ascension to lower death rate quality of change, is see by people as treatment cardiovascular disease new of turn.

强心甙类仍是治疗心衰的传统地位，自80年代以来血管紧张素转换酶抑制剂被临床广泛应用，以其独特药理基础得到迅速发展，尤其第三代新型ACEI，使心衰治疗从缓解症状上升到降低死亡率质的转变，被人们视为治疗心血管病新的转折。

the chf is the sufferer's importance reason of the heart disease , this text the last few years old age the treatment of the chf research the new progress launch discuss.strong heart mao is still treatment chf of tradition position, from 80's blood vessel strain acei drive clinical extensive application, get by its special pharmacology foundation quick development, particularly three new acei, make chf treatment put off to a later time solution symptom ascension to lower death rate quality of change, is see by people as treatment cardiovascular disease new of turn.

心衰是心脏病患者的重要原因，本文就最近几年老年心衰的治疗研究新进展展开论述。强心甙类仍是治疗心衰的传统地位，自80年代以来血管紧张素转换酶抑制剂被临床广泛应用，以其独特药理基础得到迅速发展，尤其第三代新型acei，使心衰治疗从缓解症状上升到降低死亡率质的转变，被人们视为治疗心血管病新的转折。

These findings show the value of up-titrating ARB doses to confer clinical benefit.

这些结果显示了逐步增高血管紧张素受体阻滞剂剂量在临床获益中的价值。

ARBs remain useful for controlling blood pressure in these patients, she added.

她补充说明，在这些患者中血管紧张素受体抑制剂可以用于控制血压。

ABSTRACT:Objective To study the effects of tetramethylpyrazine on calmodulin and calcinuerin in the proliferation of vascular smooth muscle cells induced by AngⅡ.

目的 探讨不同浓度川芎嗪在不同作用时间内对血管紧张素Ⅱ诱导的VSMCs增殖的抑制作用。

In rats, infusion of angiotensin II increases ferritin levels and arterial thickness which are reversed by treatment with the iron chelator deferoxamine.

在大鼠，输注血管紧张素 II 增加铁蛋白水平与动脉的厚度，可以通过铁螯合剂去铁胺的治疗来逆转。

Plunder melds and run with this jewel!

掠夺melds和运行与此宝石！

My dream is to be a crazy growing tree and extend at the edge between the city and the forest.

此刻，也许正是在通往天国的路上，我体验着这白色的晕旋。